Why Abzena?
Our focused approach.
At Abzena, we are proud to have been recognized for our growth and achievements – we could not do those without the support and trust of our customers. Thank you.
Each award and recognition is a testament to our biologic services, our values, our colleagues, and to our dedication of working with our partners and customers.
Abzena are honored to have been recognized as winner of the ‘Champion Award‘ in the ‘Biologics – Global’ category at the 2025 CDMO Leadership Awards hosted during DCAT Week in New York City. This award recognizes our commitment to quality excellence and moving our customers medicines forward. We are incredibly thankful for our biotech and pharma customers alike who helped us to win this prestigious award.
Abzena has been recognized as a winner of a 2025 CDMO Leadership Award in the “Biologics – Global” category and are a finalist for the Champion Award, recognizing our commitment to excellence in advanced drug development.
This award is in recognition of Abzena’s stellar reputation and trust among customers and industry peers, evident in the numerous nominations received from subscribers of Life Sciences Review. We are delighted and thankful to have emerged as the ‘Top Contract Manufacturing Organization 2025’ after an exhaustive evaluation by an expert panel of C-level executives, industry thought leaders, and editorial board.
Abzena was honored to be recognized as the Best Novel Treatment Development Partner 2024 in California by the 2024 Global Excellence Awards.
Abzena was recently named one of the Top 10 Contract Manufacturing Organizations in 2024 for its substantial contributions to the progression of the CDMO sector by Pharma Tech Outlook magazine.
One Nucleus recognize Abzena as the ‘Best Performing R&D Service Provider of the Year’.
Abzena were announced as the winner of the Best Contract Research (CRO) category at the World ADC Awards 2020. The World ADC awards recognise innovation, leadership and devotion in the field of Antibody Drug Conjugates (ADCs) and include nine categories designed to acknowledge the extraordinary work and commercial acumen that companies have demonstrated in order to propel these therapeutics to the forefront of cancer research.